[en] To clarify the function of cyclin A2 in colon homeostasis and colorectal cancer (CRC), we generated mice deficient for cyclin A2 in colonic epithelial cells (CECs). Colons of these mice displayed architectural changes in the mucosa and signs of inflammation, as well as increased proliferation of CECs associated with the appearance of low- and high-grade dysplasias. The main initial events triggering those alterations in cyclin A2-deficient CECs appeared to be abnormal mitoses and DNA damage. Cyclin A2 deletion in CECs promoted the development of dysplasia and adenocarcinomas in a murine colitis-associated cancer model. We next explored the status of cyclin A2 expression in clinical CRC samples at the mRNA and protein levels and found higher expression in tumors of patients with stage 1 or 2 CRC compared with those of patients with stage 3 or 4 CRC. A meta-analysis of 11 transcriptome data sets comprising 2239 primary CRC tumors revealed different expression levels of CCNA2 (the mRNA coding for cyclin A2) among the CRC tumor subtypes, with the highest expression detected in consensus molecular subtype 1 (CMS1) and the lowest in CMS4 tumors. Moreover, we found high expression of CCNA2 to be a new, independent prognosis factor for CRC tumors.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Guo, Yuchen
Gabola, Monica
Lattanzio, Rossano
Paul, Conception
Pinet, Valérie
Tang, Ruizhi
Turali, Hulya
Bremond, Julie
Longobardi, Ciro
Maurizy, Chloé ; Université de Liège - ULiège > GIGA Stem Cells - Medical Chemistry
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Dekker E, et al. Colorectal cancer. Lancet. 2019;394(10207):1467-1480.
Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. JClinPathol. 2008;61(5):561-569.
Cuyle P-J, Prenen H. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin Belg. 2017;72(2):103-115.
Kannarkatt J, et al. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. JOncol Pract. 2017;13(4):233-241.
McCleary NJ, et al. Personalizing adjuvant therapy for stage II/III colorectal cancer. Am Soc Clin Oncol Educ Book. 2017;37:232-245.
Ma H, et al. Pathology and genetics of hereditary colorectal cancer. Pathology (Phila). 2018;50(1):49-59.
Guinney J, et al. The consensus molecular subtypes of colorectal cancer. NatMed. 2015;21(11):1350-1356.
Yasmeen A, et al. E- and A-type cyclins as markers for cancer diagnosis and prognosis. ExpertRev MolDiagn. 2003;3(5):617-633.
Bendris N, et al. Cyclin A2: a genuine cell cycle regulator?. BiomolConcepts. 2012;3(6):535-543.
Blanchard JM. To be or not to be a proliferation marker?. Oncogene. 2014;33(8):954-955.
Jirawatnotai S, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230-234.
Li Z, et al. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res. 2006;66(20):9986-9994.
Li Z, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. MolCellBiol. 2006;26(11):4240-4256.
Li Z, et al. Cyclin D1 functions in cell migration. CellCycle. 2006;5(21):2440-2442.
Arsic N, et al. A novel function for cyclin A2: control of cell invasion via RhoA signalling. JCellBiol. 2012;196(1):147-162.
Bendris N, et al. Cyclin A2, a novel regulator of EMT. CellMolLifeSci. 2014;71(24):4881-4894.
Cheung CT, et al. Cyclin A2 modulates EMT via β-catenin and phospholipase C pathways. Carcinogenesis. 2015;36(8):914-924.
Wang D, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression. Oncogene. 2017;36(7):885-898.
Kanakkanthara A, et al. Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation. Science. 2016;353(6307):1549-1552.
Gopinathan L, et al. Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer Res. 2014;74(14):3870-3879.
Kalaszczynska I, et al. Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell. 2009;138(2):352-365.
el Marjou F, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis. 2004;39(3):186-193.
Minoo P, et al. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010;37(3):707-718.
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26(1):54-74.
Parisi L, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders? JImmunolRes. 2018;2018:8917804.
Laubitz D, et al. Colonic gene expression profile in NHE3-deficient mice: evidence for spontaneous distal colitis. Am J Physiol Gastrointest Liver Physiol. 2008;295(1):G63-G77.
Sobecki M, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77(10):2722-2734.
Todaro M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. CellStemCell. 2014;14(3):342-356.
Afify A, et al. The expression of CD44v6 in colon: from normal to malignant. Ann Diagn Pathol. 2016;20:19-23.
Hayashi MT, Karlseder J. DNA damage associated with mitosis and cytokinesis failure. Oncogene. 2013;32(39):4593-4601.
van den Bosch M, et al. The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep. 2003;4(9):844-849.
Rein K, Stracker TH. The MRE11 complex: an important source of stress relief. ExpCellRes. 2014;329(1):162-169.
Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature. 2016;529(7586):307-315.
Yui S, et al. YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell. 2018;22(1):35-49.
Merenda A, et al. Wnt signaling in 3D: recent advances in the applications of intestinal organoids. TrendsCellBiol. 2020;30(1):60-73.
De Robertis M, et al. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011;10:9.
Erben U, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7(8):4557-4576.
Hydbring P, et al. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280-292.
Chen W, et al. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2004;64(11):3949-3957.
Clevers H, et al. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346(6205):1248012.
Schwitalla S, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152(1-2):25-38.
Gupta PB, et al. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010-1012.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
Kim SI, et al. Cyclin-dependent kinase 2 regulates the interaction of Axin with beta-catenin. Biochem Biophys Res Commun. 2004;317(2):478-483.
Petersen BO, et al. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J. 1999;18(2):396-410.
Kabeche L, Compton DA. Cyclin A regulates kine-tochore microtubules to promote faithful chromosome segregation. Nature. 2013;502(7469):110-113.
Ganem NJ, Pellman D. Linking abnormal mitosis to the acquisition of DNA damage. J. CellBiol. 2012;199(6):871-881.
Lee Y-C, et al. High expression of phospho-H2AX predicts a poor prognosis in colorectal cancer. Anticancer Res. 2015;35(4):2447-2453.
Li J-A, et al. Cyclin A2 regulates symmetrical mitotic spindle formation and centrosome amplification in human colon cancer cells. Am J Transl Res. 2018;10(8):2669-2676.
Georgakilas AG, Kotsinas A. Editorial: DNA damage and inflammation under stress. Front Genet. 2017;8:152.
Fordyce CA, et al. Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res. 2012;14(6):R155.
Fordyce C, et al. DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res (Phila). 2010;3(2):190-201.
Jayasingam SD, et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2020;24;9:1512.
Marafini I, et al. TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets. 2013;14(12):1400-1404.
Zanconato F, et al. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29(6):783-803.
Yuen H-F, et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoSOne. 2013;8(1):54211.
Handa K, et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer. 1999;84(3):225-233.
Bahnassy AA, et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMCGastroenterol. 2004;4:22.
Nozoe T, et al. Clinicopathologic significance of cyclin A expression in colorectal carcinoma. JExp ClinCancerRes. 2004;23(1):127-133.
Li J-Q, et al. Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol. 2002;33(10):1006-1015.
Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
Bertucci F, et al. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Lett. 2014;355(1):70-75.
Eide PW, et al. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep. 2017;7(1):16618.
Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9(7):811-818.
McShane LM, et al. REporting recommendations for tumor MARKer prognostic studies. Nat Clin Pract Urol. 2005;2(8):416-422.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
